A Pilot Study of Physical Conditioning and Decitabine for Newly Diagnosed AML Patients Age ≥ 60 Who Are Not Candidates for Standard Induction Chemotherapy
Phase of Trial: Phase I
Latest Information Update: 01 Feb 2017
Price : $35 *
At a glance
- Drugs Decitabine (Primary)
- Indications Acute myeloid leukaemia
- Focus Therapeutic Use
- 31 Aug 2018 Biomarkers information updated
- 08 Jul 2016 Status changed from active, no longer recruiting to discontinued.
- 07 Oct 2015 Planned End Date changed from 1 Apr 2016 to 1 May 2017 as reported by ClinicalTrials.gov record.